Autolus Therapeutics (NASDAQ:AUTL) Sees Strong Trading Volume

Autolus Therapeutics plc (NASDAQ:AUTL - Get Free Report) shares saw an uptick in trading volume on Thursday . 1,371,456 shares changed hands during mid-day trading, a decline of 10% from the previous session's volume of 1,516,182 shares.The stock last traded at $4.09 and had previously closed at $4.21.

Analyst Ratings Changes

A number of research firms have commented on AUTL. Truist Financial raised their price target on shares of Autolus Therapeutics from $10.00 to $11.00 and gave the stock a "buy" rating in a report on Tuesday, April 9th. Needham & Company LLC reaffirmed a "buy" rating and issued a $9.00 price target on shares of Autolus Therapeutics in a research report on Friday, April 12th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $8.16.

Autolus Therapeutics Trading Down 3.1 %

The stock's 50-day simple moving average is $5.74 and its 200-day simple moving average is $5.16. The firm has a market capitalization of $1.08 billion, a P/E ratio of -3.43 and a beta of 1.90.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last announced its earnings results on Thursday, March 14th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.18). On average, equities research analysts expect that Autolus Therapeutics plc will post -0.71 EPS for the current year.

Institutional Trading of Autolus Therapeutics

Several hedge funds have recently made changes to their positions in the company. Trust Co. of Toledo NA OH bought a new stake in Autolus Therapeutics in the 3rd quarter valued at about $84,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of Autolus Therapeutics in the fourth quarter valued at approximately $105,000. EWA LLC lifted its stake in shares of Autolus Therapeutics by 40.2% during the 4th quarter. EWA LLC now owns 25,678 shares of the company's stock valued at $155,000 after buying an additional 7,361 shares in the last quarter. Rathbones Group PLC bought a new position in Autolus Therapeutics in the 3rd quarter worth approximately $171,000. Finally, Sierra Summit Advisors LLC purchased a new position in Autolus Therapeutics in the 4th quarter valued at approximately $275,000. 72.83% of the stock is currently owned by institutional investors.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.